Covered recipient · General Payments record
ADAM WHITTINGTON
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$498.15
- Reported across 21 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $343.96 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $98.43 | 5 |
| GENZYME CORPORATION | $93.85 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $41.36 | 2 |
| Galderma Laboratories, L.P. | $36.41 | 2 |
| ConvaTec Inc. | $32.17 | 1 |
| Lilly USA, LLC | $14.82 | 1 |
| E.R. Squibb & Sons, L.L.C. | $13.47 | 1 |
| Amgen Inc. | $13.45 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $15.31 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106334087 | CMS |
| ABBVIE INC. | $20.13 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106334089 | CMS |
| ABBVIE INC. | $23.90 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106334091 | CMS |
| ABBVIE INC. | $18.83 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106334093 | CMS |
| ABBVIE INC. | $20.26 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106334095 | CMS |
| Amgen Inc. | $13.45 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117414558 | CMS |
| ConvaTec Inc. | $32.17 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151386942 | CMS |
| E.R. Squibb & Sons, L.L.C. | $13.47 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101342443 | CMS |
| Galderma Laboratories, L.P. | $19.38 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145335333 | CMS |
| Galderma Laboratories, L.P. | $17.03 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145335335 | CMS |
| GENZYME CORPORATION | $20.51 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139752473 | CMS |
| GENZYME CORPORATION | $22.60 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139752491 | CMS |
| GENZYME CORPORATION | $24.12 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139752515 | CMS |
| GENZYME CORPORATION | $26.62 | 11/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139752553 | CMS |
| Lilly USA, LLC | $14.82 | 01/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136009037 | CMS |
| Novartis Pharmaceuticals Corporation | $14.42 | 02/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087428948 | CMS |
| Novartis Pharmaceuticals Corporation | $26.94 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087428950 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.